Sugi Predict

Sugi Predict / Compounds / SCHEMBL407460

SCHEMBL407460

SCHEMBL407460

CCOC(=O)N1CCc2[nH]c3ccc(C)cc3c2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 1.00
▸ PABPC1 P11940 1/20 1.00
▸ ATM Q13315 1/20 1.00
▸ SMN1; SMN2 Q16637 1/20 1.00
▸ BAZ2B Q9UIF8 6/20 0.74
▸ NPC1 O15118 1/20 0.66
▸ ALDH1A1 P00352 6/20 0.64
▸ GAA P10253 3/20 0.64
▸ MAPT P10636 3/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ CASP1 P29466 2/20 0.64
▸ CASP7 P55210 2/20 0.64
▸ USP2 O75604 1/20 0.64
▸ KDM4E B2RXH2 2/20 0.59
▸ POLB P06746 1/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL620615 0.93 LMNA (0.87) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL11760636 0.89 SMN1; SMN2 (0.80) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL764099 0.88 LMNA (0.79) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL10777655 0.88 SMN1; SMN2 (0.79) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL12868340 0.88 LMNA (0.79) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL12868564 0.87 LMNA (0.78) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL541660 0.87 LMNA (0.78) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL2832897 0.86 LMNA (0.76) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL940424 0.85 LMNA (0.74) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL12868355 0.85 BAZ2B (1.00) LMNAPABPC1ATMSMN1; SMN2BAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 — — US disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 — — US disclosed
US-10172827-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-08 — — US disclosed
US-10172827-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-08 — — US disclosed
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 — — US disclosed
EP-2385829-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2018-08-01 — — EP disclosed
EP-2385829-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2018-08-01 — — EP disclosed
EP-3013824-B1 CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ALZPROTECT (FR) 2018-05-16 — — EP disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 — — US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 — — US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 — — US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 — — US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 — — US disclosed
EP-2217598-A1 NEW TETRACYCLIC COMPOUNDS Medivation Technologies, Inc. (US) 2010-08-18 — — EP disclosed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 — — WO disclosed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 — — WO disclosed
EP-2184064-A2 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF Alla Chem, LLC. (US) 2010-05-12 — — EP disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 — — US disclosed
WO-2009055828-A1 NEW TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2009-04-30 — — WO disclosed
WO-2008060190-A2 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF ALLA CHEM, LLC (US) 2008-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172827-B2 Pro-neurogenic compounds DCX, GAP43, BDNF LMNA 654/4885PABPC1 3066/4885ATM 4515/4885
US-20180127367-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX LMNA 174/4885PABPC1 4206/4885ATM 2483/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX LMNA 174/4885PABPC1 4206/4885ATM 2483/4885
US-10183011-B2 Anti-depression compounds BDNF, DCX, GAP43 LMNA 523/4885PABPC1 4248/4885ATM 2199/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF LMNA 628/4885PABPC1 3085/4885ATM 4519/4885
US-20090239854-A1 Tetracyclic compounds HTR2C, HTR3D, HTR5A LMNA 4777/4885PABPC1 4460/4885ATM 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.